Evidence map›Paper›PMID 42441209›Full record

ArticleRSC advances2026

Structural design and cytotoxic profiling of a novel 1,3,4-thiadiazole derivative targeting MCF-7 and HCT-116 cell lines: synthesis, cytotoxicity, and

Mostafa Sayed, Ehdaa Mohammed, Doha H Aboubaker, Ahmed A El-Rashedy, Reda Hassanien, Mahmoud S Tolba, Mostafa Ahmed

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mostafa SayedSchool of Materials and Chemistry, Southwest University of Science and Technology Mianyang 621010 China.ORCID https://orcid.org/0000-0002-5469-0129
Ehdaa MohammedDepartment of Chemistry, Faculty of Science, New Valley University El-Kharja 72511 Egypt drmostafa@scinv.au.edu.eg.
Doha H AboubakerMedicinal and Aromatic Plants Department, Pharmaceutical and Drug Industries Institute, National Research Centre Dokki Giza 12622 Egypt.
Ahmed A El-RashedyNatural and Microbial Products Department, National Research Center (NRC) Cairo 12622 Egypt.
Reda HassanienDepartment of Chemistry, Faculty of Science, New Valley University El-Kharja 72511 Egypt drmostafa@scinv.au.edu.eg.
Mahmoud S TolbaDepartment of Chemistry, Faculty of Science, New Valley University El-Kharja 72511 Egypt drmostafa@scinv.au.edu.eg.
Mostafa AhmedDepartment of Chemistry, Faculty of Science, New Valley University El-Kharja 72511 Egypt drmostafa@scinv.au.edu.eg.ORCID https://orcid.org/0000-0002-3264-9299

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains a leading cause of mortality worldwide, necessitating the continuous development of more effective and selective therapeutic agents. Among heterocyclic scaffolds, 1,3,4-thiadiazole derivatives have attracted considerable attention due to their diverse pharmacological properties and favorable physicochemical characteristics. In this study, a novel thiadiazole-based compound namely 2-((5-acetamido-1,3,4-thiadiazol-2-yl)thio)-

Identifiers

PMID42441209
PMCPMC13334768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.